Searching for just a few words should be enough to get started. If you need to make more complex queries, use the tips below to guide you.
Issue title: Alzheimer’s Disease: New Beginnings
Guest editors: G. Perry, J. Avila, P.I. Moreira, A.A. Sorensen and M. Tabaton
Article type: Review Article
Authors: Bennett, David A.a; b; * | Buchman, Aron S.a; b | Boyle, Patricia A.a; c | Barnes, Lisa L.a; b; c | Wilson, Robert S.a; b; c | Schneider, Julie A.a; b; d
Affiliations: [a] Rush Alzheimer’s Disease Center, Rush University Medical Center, Chicago, IL, USA | [b] Department of Neurological Sciences, Rush University Medical Center, Chicago, IL, USA | [c] Department of Behavioral Sciences, Rush University Medical Center, Chicago, IL, USA | [d] Department of Pathology (Neuropathology), Rush University Medical Center, Chicago, IL, USA
Correspondence: [*] Correspondence to: David A. Bennett, MD, Rush Alzheimer’s Disease Center, Rush University Medical Center, 1750W Harrison, Suite 1000, Chicago, IL 60612, USA. E-mail: David_A_Bennett@Rush.edu.
Abstract: Background:The Religious Orders Study and Rush Memory and Aging Project are both ongoing longitudinal clinical-pathologic cohort studies of aging and Alzheimer’s disease (AD). Objectives:To summarize progress over the past five years and its implications for understanding neurodegenerative diseases. Methods:Participants in both studies are older adults who enroll without dementia and agree to detailed longitudinal clinical evaluations and organ donation. The last review summarized findings through the end of 2011. Here we summarize progress and study findings over the past five years and discuss new directions for how these studies can inform on aging and AD in the future. Results:We summarize 1) findings on the relation of neurobiology to clinical AD; 2) neurobiologic pathways linking risk factors to clinical AD; 3) non-cognitive AD phenotypes including motor function and decision making; 4) the development of a novel drug discovery platform. Conclusion:Complexity at multiple levels needs to be understood and overcome to develop effective treatments and preventions for cognitive decline and AD dementia.
Keywords: Alzheimer’s disease, cognitive decline, decision making, dementia, drug discovery, epidemiology, motor function, neuropathology, omics
DOI: 10.3233/JAD-179939
Journal: Journal of Alzheimer's Disease, vol. 64, no. s1, pp. S161-S189, 2018
IOS Press, Inc.
6751 Tepper Drive
Clifton, VA 20124
USA
Tel: +1 703 830 6300
Fax: +1 703 830 2300
sales@iospress.com
For editorial issues, like the status of your submitted paper or proposals, write to editorial@iospress.nl
IOS Press
Nieuwe Hemweg 6B
1013 BG Amsterdam
The Netherlands
Tel: +31 20 688 3355
Fax: +31 20 687 0091
info@iospress.nl
For editorial issues, permissions, book requests, submissions and proceedings, contact the Amsterdam office info@iospress.nl
Inspirees International (China Office)
Ciyunsi Beili 207(CapitaLand), Bld 1, 7-901
100025, Beijing
China
Free service line: 400 661 8717
Fax: +86 10 8446 7947
china@iospress.cn
For editorial issues, like the status of your submitted paper or proposals, write to editorial@iospress.nl
如果您在出版方面需要帮助或有任何建, 件至: editorial@iospress.nl